Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SS1
MCID: SRC025
MIFTS: 70

Sarcoidosis 1 (SS1)

Categories: Bone diseases, Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Sarcoidosis 1

About this section

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 56 73 6
Sarcoidosis 56 12 74 52 58 73 54 42 43 15 62 71 32
Boeck Sarcoid 56 12 58 73
Sarcoidosis, Susceptibility to, 1 56 13
Besnier-Boeck-Schaumann Disease 58 73
Ss1 56 73
Sarcoidosis, Susceptibility to, Type 1 39
Lymphogranulomatosis 12
Schaumann's Disease 52
Sarcoid of Boeck 52
Hodgkin Disease 71

Characteristics:

Orphanet epidemiological data:

58
sarcoidosis
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide),1-5/10000 (Europe); Age of onset: Adult;

OMIM:

56
Miscellaneous:
generalized fatigue
onset usually before age 40 years
systemic granulomatous disease
u.s. frequency higher in blacks than whites

Inheritance:
autosomal dominant


HPO:

31
sarcoidosis 1:
Inheritance autosomal dominant inheritance sporadic


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Immune diseases Neuronal diseases Eye diseases Nephrological diseases Respiratory diseases Bone diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare endocrine diseases


Sources

Summaries for Sarcoidosis 1

About this section
NIH Rare Diseases : 52 Sarcoidosis is an inflammatory disease characterized by the development and growth of tiny lumps of cells called granulomas. If these tiny granulomas grow and clump together in an organ , they can affect the organ's structure and function. Overtime, this can lead to permanent scarring or thickening of the organ tissue (also called fibrosis). Although the granulomas can be found in almost any part of the body, they occur most commonly in the lungs and lymph nodes . Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The exact cause of sarcoidosis is poorly understood. In many cases, treatment is not necessary and sarcoidosis will resolve on its own. However, therapies such as corticosteroids , immunosuppressants, and antimalarial drugs, are available to control symptoms, prevent complications, and improve outcomes.

MalaCards based summary : Sarcoidosis 1, also known as sarcoidosis, is related to cardiac sarcoidosis and skin sarcoidosis, and has symptoms including snoring and coughing. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Riociguat have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotypes are fatigue and fever

Disease Ontology : 12 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

MedlinePlus : 42 Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body. No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include Cough Shortness of breath Weight loss Night sweats Fatigue Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute

UniProtKB/Swiss-Prot : 73 Sarcoidosis 1: An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

PubMed Health : 62 About sarcoidosis: Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances. For example, it sends special cells to protect organs that are in danger. These cells release chemicals that recruit other cells to isolate and destroy the harmful substance. Inflammation occurs during this process. Once the harmful substance is gone, the cells and the inflammation go away. In people who have sarcoidosis, the inflammation doesn't go away. Instead, some of the immune system cells cluster to form lumps called granulomas (gran-yu-LO-mas) in various organs in your body.

Wikipedia : 74 Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as... more...

More information from OMIM: 181000
Sources

Related Diseases for Sarcoidosis 1

About this section

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2 Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1548)
# Related Disease Score Top Affiliating Genes
1 cardiac sarcoidosis 35.1 TNF IL1B IFNG ACE
2 skin sarcoidosis 34.8 TNF ACE
3 blau syndrome 34.7 TNF NOD2 IL1B
4 beryllium disease 33.5 TNF HLA-DRB1
5 orofacial granulomatosis 33.4 TNF NOD2 IFNG CXCR3 CCL3 BTNL2
6 retinal vasculitis 33.4 CCR6 CCL2 ACE
7 intermediate uveitis 33.3 TNF IL2RA IFNG HLA-DRB1 CXCR3 CCR6
8 interstitial lung disease 33.2 TNF IL1B IL18 IFNG CXCL9 CCL2
9 melkersson-rosenthal syndrome 32.8 TNF ACE
10 uveitis 32.3 TNF NOD2 IL2RA IFNG CXCR3 CCL2
11 pulmonary fibrosis 32.1 IL1B CXCR3 CCL3 CCL2 CCL18
12 lung disease 31.9 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
13 glomerulonephritis 31.7 SCGB1A1 IL1B CCL2 ACE
14 idiopathic interstitial pneumonia 31.7 IFNG CCR6 CCL2
15 panuveitis 31.7 TNF NOD2 HLA-DRB1 CCR6 ACE
16 pulmonary tuberculosis 31.7 TNF IL2RA IL18 IL12RB1 IFNG HLA-DRB1
17 exanthem 31.7 TNF CCR6 ACE
18 extrinsic allergic alveolitis 31.6 IL2RA IL1B IL18 CXCR3 CCR6 CCL3
19 lymphopenia 31.6 IL2RA IL18 IFNG CCR6
20 posterior uveitis 31.6 TNF IL2RA IFNG CCR6
21 myocarditis 31.6 TNF IL1B IL18 IL12RB1 IFNG CCL2
22 autoimmune disease 31.6 TNF IL2RA IL1B IL18 IFNG HLA-DRB1
23 leprosy 3 31.6 TNF NOD2 IL1B IFNG HLA-DRB1 CCR6
24 respiratory failure 31.6 TNF SERPINA3 SCGB1A1 IL1B ACE
25 allergic hypersensitivity disease 31.6 TNF IFNG CCR6 CCL3
26 histoplasmosis 31.5 TNF IFNG HLA-DRB1 CCR6
27 chronic beryllium disease 31.5 TNF IFNG HLA-DRB1
28 crohn's disease 31.5 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
29 macular retinal edema 31.5 TNF CCL2 ACE
30 myositis 31.5 TNF SERPINA3 IL1B IFNG HLA-DRB1 BTNL2
31 spondylitis 31.5 TNF NOD2 IFNG CCR6
32 choroiditis 31.4 TNF IFNG ACE
33 pulmonary fibrosis, idiopathic 31.4 TNF SCGB1A1 IL1B IL18 IFNG CXCR3
34 mycobacterium tuberculosis 1 31.4 TNF SERPINA3 NOD2 IL18 IL12RB1 IFNG
35 optic nerve disease 31.4 TNF SERPINA3 CCR6 ACE
36 histiocytosis 31.4 TNF SERPINA3 CCR6
37 iritis 31.4 TNF NOD2 CCR6 ACE
38 syphilis 31.4 HLA-DRB1 CCR6 ACE
39 primary biliary cirrhosis 31.4 TNF IL2RA IL1B IL12RB1 IFNG HLA-DRB1
40 pleurisy 31.4 TNF IFNG CCL3 CCL2
41 pneumoconiosis 31.4 TNF SCGB1A1 IL1B CCL2
42 cryptococcosis 31.4 TNF IFNG CCR6
43 common variable immunodeficiency 31.4 TNF NOD2 IL2RA IL12RB1 IFNG
44 systemic scleroderma 31.3 TNF IFNG CCR6 ACE
45 hydrocephalus 31.3 TNF SERPINA3 IL18 IFNG ACE
46 meningitis 31.3 TNF IL1B IL18 IFNG CCL3 CCL2
47 ulcerative colitis 31.3 TNF NOD2 IL1B IFNG HLA-DRB1 CCR6
48 pericarditis 31.3 TNF IL1B IFNG ACE
49 thrombocytopenia 31.3 TNF IL1B IL18 IFNG CCL2
50 arthritis 31.3 TNF NOD2 IL1B IL18 IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Sarcoidosis 1:



Diseases related to Sarcoidosis 1
Sources

Symptoms & Phenotypes for Sarcoidosis 1

About this section

Human phenotypes related to Sarcoidosis 1:

58 31 (show top 50) (show all 93)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
2 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
3 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
4 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
5 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
6 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
7 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
8 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
9 uveitis 58 31 frequent (33%) Frequent (79-30%) HP:0000554
10 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
11 erythema nodosum 58 31 frequent (33%) Frequent (79-30%) HP:0012219
12 increased t cell count 31 frequent (33%) HP:0100828
13 facial palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0010628
14 cataract 58 31 occasional (7.5%) Occasional (29-5%) HP:0000518
15 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
16 alopecia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001596
17 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
18 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
19 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
20 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
21 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
22 emphysema 58 31 occasional (7.5%) Occasional (29-5%) HP:0002097
23 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
24 heart block 58 31 occasional (7.5%) Occasional (29-5%) HP:0012722
25 hypercalciuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0002150
26 keratoconjunctivitis sicca 58 31 occasional (7.5%) Occasional (29-5%) HP:0001097
27 diabetes insipidus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000873
28 glaucoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0000501
29 hepatic failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001399
30 nephrocalcinosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000121
31 nephrolithiasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000787
32 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
33 hypopigmentation of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0001010
34 upper airway obstruction 58 31 occasional (7.5%) Occasional (29-5%) HP:0002781
35 proximal muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003701
36 abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0011024
37 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
38 bone cyst 58 31 occasional (7.5%) Occasional (29-5%) HP:0012062
39 bronchiectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002110
40 hyperpigmentation of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0000953
41 pneumothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0002107
42 increased csf protein 58 31 occasional (7.5%) Occasional (29-5%) HP:0002922
43 ventricular tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004756
44 skin plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0200035
45 tubulointerstitial nephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001970
46 abnormality of the nasal mucosa 58 31 occasional (7.5%) Occasional (29-5%) HP:0000433
47 dacryocystitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000620
48 enlarged lacrimal glands 58 31 occasional (7.5%) Occasional (29-5%) HP:0007734
49 chylothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0010310
50 enlargement of parotid gland 58 31 occasional (7.5%) Occasional (29-5%) HP:0011801

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Eyes:
photophobia
glaucoma
uveitis
blurred vision
chorioretinitis
more
Respiratory:
dyspnea
cough

Abdomen Gastrointestinal:
anorexia
associated inflammatory bowel disease

Immunology:
generalized lymphadenopathy
hyperglobulinemia
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes

Head And Neck Mouth:
enlarged salivary glands

Abdomen Liver:
hepatomegaly may occur
elevated liver function tests may occur

Neurologic Central Nervous System:
neurosarcoidosis (5-16% of patients)

Metabolic Features:
fever

Growth Weight:
weight loss

Laboratory Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Skeletal:
polyarthritis
bone cysts

Respiratory Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Abdomen Spleen:
splenomegaly may occur

Hematology:
bone marrow involvement may cause pancytopenia

Clinical features from OMIM:

181000

UMLS symptoms related to Sarcoidosis 1:


snoring, coughing

MGI Mouse Phenotypes related to Sarcoidosis 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACE CCR6 CXCR3 IFNG IL12RB1 IL18
2 immune system MP:0005387 9.44 ACE CCL2 CCR6 CHIT1 CXCR3 IFNG
Sources

Drugs & Therapeutics for Sarcoidosis 1

About this section

PubMed Health treatment related to Sarcoidosis 1: 62

Not everyone who has sarcoidosis needs treatment . Sometimes the disease goes away on its own. Whether you need treatment and what type of treatment you need depend on your signs and symptoms, which organs are affected, and whether those organs are working well. If the disease affects certain organs —such as your eyes , heart , or brain —you'll need treatment even if you don't have any symptoms. In either case, whether you have symptoms or not, you should see your doctor for ongoing care. He or she will want to check to make sure that the disease isn't damaging your organs . For example, you may need routine lung function tests to make sure that your lungs are working well. If the disease isn't worsening, your doctor may watch you closely to see whether the disease goes away on its own. If the disease does start to get worse, your doctor can prescribe treatment . The goals of treatment include: Relieving symptoms Improving organ function Controlling inflammation and reducing the size of granulomas (inflamed lumps) Preventing pulmonary fibrosis (lung scarring ) if your lungs are affected Your doctor may prescribe topical treatments and/or medicines to treat the disease.

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Riociguat Approved Phase 4 625115-55-1
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Racepinephrine Approved Phase 4 329-65-7 838
8
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
Etoposide Approved Phase 4 33419-42-0 36462
14
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
15
Epirubicin Approved Phase 4 56420-45-2 41867
16
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
17
Nicotine Approved Phase 4 54-11-5 942 89594
18
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
22 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
23
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
24
leucovorin Approved Phase 4 58-05-9 6006 143
25
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
30 Epinephryl borate Phase 4
31 Adrenergic Agonists Phase 4
32 Narcotics Phase 4
33 Adrenergic alpha-2 Receptor Agonists Phase 4
34 Analgesics, Opioid Phase 4
35 Adrenergic Agents Phase 4
36 Dopamine Uptake Inhibitors Phase 4
37 Dopamine Agents Phase 4
38 Dexmethylphenidate Hydrochloride Phase 4
39 Central Nervous System Depressants Phase 4
40 Hypnotics and Sedatives Phase 4
41 Anesthetics, General Phase 4
42 Anesthetics, Intravenous Phase 4
43 Topoisomerase Inhibitors Phase 4
44 Gastrointestinal Agents Phase 4
45 Autonomic Agents Phase 4
46 Antiemetics Phase 4
47 Neuroprotective Agents Phase 4
48 Anticoagulants Phase 4
49 Citrate Phase 4
50 Ergocalciferols Phase 4

Interventional clinical trials:

(show top 50) (show all 965)
# Name Status NCT ID Phase Drugs
1 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
2 ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
3 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
4 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
6 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
8 Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. Completed NCT00361387 Phase 4 d-methylphenidate
9 Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel Completed NCT02298491 Phase 4 H.P. Acthar Gel
10 Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. Completed NCT02246023 Phase 4
11 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
12 Vitamin D Homeostasis in Sarcoidosis Recruiting NCT03621553 Phase 4 Ergocalciferol;Placebo;Calcium Citrate with Vitamin D2
13 ACTHAR Therapy for Central Nervous System Sarcoidosis Recruiting NCT02920710 Phase 4 Repository Corticotropin Injection
14 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis Recruiting NCT03320070 Phase 4 repository corticotropin injection;Placebo
15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Recruiting NCT03549598 Phase 4 68Ga-DOTATATE PET/CT;18FDG PET/CT scan;13NH3 PET/CT scan
16 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
17 Pirfenidone for Progressive Fibrotic Sarcoidosis Recruiting NCT03260556 Phase 4 Pirfenidone;Placebos
18 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
19 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
20 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
21 Use of CXCL9 as a Biomarker of Acthar Efficacy Not yet recruiting NCT02523092 Phase 4 Acthar gel
22 Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors Suspended NCT00701207 Phase 4 nicotine patch
23 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
24 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
25 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
26 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
27 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
28 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
29 ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial Unknown status NCT02348905 Phase 2, Phase 3 ACTHAR Gel 40 units twice weekly;ACTHAR Gel 80 units twice weekly.
30 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
31 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
32 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
33 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
34 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
35 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
36 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
37 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
38 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
39 Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00851929 Phase 2, Phase 3 Ambrisentan
40 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Completed NCT01324999 Phase 2, Phase 3 Tadalafil
41 Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis Completed NCT00305552 Phase 3 THALIDOMIDE
42 The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis Completed NCT00794274 Phase 2, Phase 3 CC-100004
43 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
44 Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. Completed NCT01687517 Phase 3 Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
45 Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis Completed NCT00555347 Phase 2, Phase 3 Armodafinil;Placebo
46 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
47 Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial Completed NCT00872612 Phase 3
48 A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade�) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement. Completed NCT00073437 Phase 3 Infliximab
49 Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00581607 Phase 2, Phase 3 Bosentan;Placebo;Bosentan;Placebo
50 Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: sarcoidosis

Sources

Genetic Tests for Sarcoidosis 1

About this section
Sources

Anatomical Context for Sarcoidosis 1

About this section

MalaCards organs/tissues related to Sarcoidosis 1:

40
Lung, T Cells, Lymph Node, Skin, Heart, Testes, Bone
Sources

Publications for Sarcoidosis 1

About this section

Articles related to Sarcoidosis 1:

(show top 50) (show all 23363)
# Title Authors PMID Year
1
HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. 61 56 6
14508706 2003
2
Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. 54 61 56
15702130 2005
3
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. 54 61 6
15735647 2005
4
Association between IFNA genotype and the risk of sarcoidosis. 54 61 56
15004750 2004
5
Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. 61 56
17591867 2007
6
Demographic-related variations in posterior segment ocular sarcoidosis. 61 56
15019390 2004
7
Results from a genome-wide search for predisposing genes in sarcoidosis. 61 56
11549543 2001
8
Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. 61 56
10580780 1999
9
[Familial sarcoidosis. 4 cases from 2 families]. 61 56
3070740 1988
10
Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. 61 56
3827423 1987
11
Familial occurrence of sarcoidosis and Crohn's disease. 61 56
6134089 1983
12
Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. 61 56
1067023 1976
13
Familial sarcoidosis: a possible genetic influence. 61 56
1067024 1976
14
Sarcoidosis and Crohn disease in siblings. 61 56
5558992 1971
15
Familial sarcoidosis. Report of four siblings with acute sarcoidosis. 61 56
5558993 1971
16
SARCOIDOSIS. I. FAMILIAL OCCURRENCE. II. PSEUDOTUMOR CEREBRI AND UNUSUAL SKIN LESIONS. 61 56
14104643 1964
17
Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. 61 56
13874291 1961
18
New advances in the management of pulmonary sarcoidosis. 61 42
31641045 2019
19
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. 61 42
31321613 2019
20
Rare involvement of paranasal sinuses in sarcoidosis: case report and literature review. 61 42
31692793 2019
21
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature. 54 61
20162506 2010
22
The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. 54 61
20070603 2010
23
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 54 61
19467619 2010
24
Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. 54 61
19910611 2010
25
CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. 54 61
19679608 2010
26
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. 54 61
19147181 2010
27
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 54 61
20082271 2010
28
A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. 54 61
19854854 2010
29
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. 54 61
19808030 2010
30
Targeting the TNF-alpha pathway in sarcoidosis. 54 61
20001207 2010
31
Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. 54 61
20022779 2010
32
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis. 54 61
20151281 2010
33
Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. 54 61
19966199 2009
34
Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. 54 61
20011602 2009
35
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. 54 61
19755199 2009
36
[Radiographic healing of sarcoid bone erosion]. 54 61
19756665 2009
37
Antimycobacterial immune responses in patients with pulmonary sarcoidosis. 54 61
20298409 2009
38
CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. 54 61
19386686 2009
39
Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. 54 61
19225544 2009
40
Hypothesis: sarcoidosis is a STAT1-mediated disease. 54 61
19464956 2009
41
Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation. 54 61
19842835 2009
42
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. 54 61
19259660 2009
43
Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. 54 61
19359344 2009
44
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). 54 61
19585358 2009
45
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 54 61
19117745 2009
46
Atypical sarcoidosis: case reports and review of the literature. 54 61
19530510 2009
47
Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. 54 61
19281539 2009
48
Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. 54 61
19220835 2009
49
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. 54 61
19077082 2009
50
Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? 54 61
19208587 2009
Sources

Variations for Sarcoidosis 1

About this section

ClinVar genetic disease variations for Sarcoidosis 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-DRB1 HLA-DRB1, HLA-DRB1*1101undetermined variant risk factor 14905
Sources

Expression for Sarcoidosis 1

About this section
Search GEO for disease gene expression data for Sarcoidosis 1.
Sources

Pathways for Sarcoidosis 1

About this section

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.06 TNF SERPINA3 NOD2 IL2RA IL1B IL18
2
ERK Signaling 63
Show member pathways
 13.85 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
3
PEDF Induced Signaling 63
Show member pathways
 13.7 TNF IL2RA IL1B IL18 IL12RB1 IFNG
4
TGF-Beta Pathway 63
Show member pathways
 13.58 TNF IL2RA IL1B IL18 IL12RB1 IFNG
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 TNF NOD2 IL2RA IL1B IL18 IL12RB1
6
Akt Signaling 63
Show member pathways
 13.4 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
7
PAK Pathway 63
Show member pathways
 13.21 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
8
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.15 TNF NOD2 IL1B IL18 IFNG CXCL9
9
CCR5 Pathway in Macrophages 63
Show member pathways
 12.92 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
10
Allograft rejection 1 36
Show member pathways
 12.89 TNF IL2RA IL1B IFNG HLA-DRB1 CXCL9
11
Measles 36
Show member pathways
 12.87 TNF IL2RA IL1B IL18 IFNG HLA-DRB1
12
Herpes simplex virus 1 infection 36
12.81 TNF IL1B IFNG HLA-DRB1 CCL2
13
Immune response NFAT in immune response 22
Show member pathways
 12.69 TNF IL2RA IL18 IL12RB1 IFNG HLA-DRB1
14
Immune response IL-23 signaling pathway 22
Show member pathways
 12.62 TNF IL1B IL18 IL12RB1 IFNG CXCL9
15
NF-kappaB Signaling 4
12.61 TNF IL2RA IL1B IFNG CCL2
16
Th17 cell differentiation 36
Show member pathways
 12.51 TNF NOD2 IL2RA IL1B IL18 IL12RB1
17
Folate Metabolism 1
Show member pathways
 12.39 TNF SERPINA3 IL1B IFNG CCL2
18
IL-17 Family Signaling Pathways 64
Show member pathways
 12.35 TNF IL1B IFNG CCL2
19
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.31 TNF IL2RA IL1B IL18 IFNG
20
Toxoplasmosis 36
Show member pathways
 12.29 TNF IL1B IFNG HLA-DRB1
21
NOD-like receptor signaling pathway 36
12.29 TNF NOD2 IL1B IL18 CCL2
22
Tuberculosis 36
12.26 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
23
Fluid shear stress and atherosclerosis 36
12.14 TNF IL1B IFNG CCL2
24
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.14 TNF IL2RA IL18 CXCR3 CXCL9 CCR6
25
Th1 Differentiation Pathway 64
Show member pathways
 12.12 TNF IL1B IL18 IL12RB1 IFNG
26
Yersinia infection 36
12.06 TNF IL1B IL18 CCL2
27
Spinal Cord Injury 1
12.06 TNF IL1B IFNG CCL2
28
Interleukin-4 and 13 signaling 65
12.03 TNF IL1B IL18 CCL2
29
TNF signaling pathway 36
12.02 TNF NOD2 IL1B CCL2
30
Hematopoietic cell lineage 36
11.96 TNF IL2RA IL1B HLA-DRB1
31
IL12-mediated signaling events 1
Show member pathways
 11.92 IL2RA IL1B IL18 IL12RB1 IFNG HLA-DRB1
32
Salmonella infection (KEGG) 36
11.85 IL1B IL18 IFNG CCL3
33
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.78 TNF IL2RA IFNG
34
Dendritic Cells Developmental Lineage Pathway 64
11.77 TNF IL1B IFNG
35
Rheumatoid arthritis 36
11.77 TNF IL1B IL18 IFNG HLA-DRB1 CCL3
36
Lung fibrosis 1
11.73 TNF IL1B CCL3 CCL2
37
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 TNF IL1B IFNG
38
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.68 TNF IL2RA IFNG
39
Legionellosis 36
11.64 TNF IL1B IL18
40
Malaria 36
11.57 TNF IL1B IL18 IFNG CCL2
41
Aryl Hydrocarbon Receptor Pathway 1
11.56 TNF IL1B IFNG
42
Interleukin-10 signaling 65
11.54 TNF IL1B IL18 CCL3 CCL2
43
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.53 TNF IL1B IFNG
44
MSP-RON Signaling 63
11.51 TNF IL1B IL18 IFNG CCL2
45
Nucleotide-binding Oligomerization Domain (NOD) pathway 1
11.49 NOD2 IL1B IL18
46
African trypanosomiasis 36
11.47 TNF IL1B IL18 IFNG
47
Type II interferon signaling (IFNG) 1
11.43 IL1B IFNG CXCL9
48
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.41 TNF IL1B IL18 IFNG CXCL9 CCL3
49
Development and heterogeneity of the ILC family 1
11.4 TNF IL1B IL18 IFNG
50
Cytokines and Inflammatory Response 1
11.34 TNF IL1B IFNG HLA-DRB1
Sources

GO Terms for Sarcoidosis 1

About this section

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
2 cell surface GO:0009986 9.73 TNF NOD2 IL2RA HLA-DRB1 CXCR3 CCR6
3 extracellular space GO:0005615 9.73 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
4 external side of plasma membrane GO:0009897 9.28 TNF IL2RA IL12RB1 HLA-DRB1 CXCR3 CXCL9

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 SCGB1A1 IL1B IL18 IL12RB1 CXCR3 CXCL9
2 positive regulation of gene expression GO:0010628 10.1 TNF IL1B IL18 IFNG CCL3
3 cell surface receptor signaling pathway GO:0007166 10.02 IL2RA IFNG CXCR3 CCL2
4 cell-cell signaling GO:0007267 10.02 IL1B IL18 CXCL9 CCL3 CCL18
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF NOD2 CCL3 CCL2 CCL18
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TNF NOD2 IL1B IL18
7 cellular response to lipopolysaccharide GO:0071222 9.97 TNF NOD2 IL1B CXCL9 CCL2
8 MAPK cascade GO:0000165 9.97 TNF IL2RA IL1B IL18 CCL3 CCL2
9 cellular response to interferon-gamma GO:0071346 9.93 IL12RB1 CCL3 CCL2 CCL18
10 cell chemotaxis GO:0060326 9.92 CXCR3 CCR6 CCL3 CCL2
11 positive regulation of inflammatory response GO:0050729 9.91 TNF IL1B IL18 CCL3
12 chemotaxis GO:0006935 9.91 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
13 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL2RA IL1B IL18 IL12RB1 CCL3
14 positive regulation of JNK cascade GO:0046330 9.9 TNF NOD2 IL1B
15 calcium-mediated signaling GO:0019722 9.9 CXCR3 CCR6 CCL3
16 cellular response to interleukin-1 GO:0071347 9.9 CCL3 CCL2 CCL18
17 regulation of inflammatory response GO:0050727 9.9 TNF SCGB1A1 NOD2
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF IL18 IFNG
19 regulation of insulin secretion GO:0050796 9.88 TNF IL1B IFNG
20 positive regulation of T cell proliferation GO:0042102 9.88 IL2RA IL1B BTNL2
21 positive regulation of interleukin-6 production GO:0032755 9.87 TNF NOD2 IL1B
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF NOD2 IL1B IL18
23 positive regulation of phagocytosis GO:0050766 9.85 TNF IL1B IFNG
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
25 negative regulation of T cell proliferation GO:0042130 9.85 SCGB1A1 IL2RA HLA-DRB1
26 monocyte chemotaxis GO:0002548 9.85 CCL3 CCL2 CCL18
27 neutrophil chemotaxis GO:0030593 9.85 IL1B CXCL9 CCL3 CCL2 CCL18
28 humoral immune response GO:0006959 9.84 TNF IFNG CCR6 CCL2
29 lymphocyte chemotaxis GO:0048247 9.83 CCL3 CCL2 CCL18
30 positive regulation of interleukin-8 production GO:0032757 9.83 TNF NOD2 IL1B
31 positive regulation of activated T cell proliferation GO:0042104 9.83 IL2RA IL18 IL12RB1
32 positive regulation of interferon-gamma production GO:0032729 9.81 TNF IL1B IL18 IL12RB1
33 protein kinase B signaling GO:0043491 9.78 TNF IL1B CCL3 CCL2
34 eosinophil chemotaxis GO:0048245 9.77 CCL3 CCL2 CCL18
35 astrocyte activation GO:0048143 9.77 TNF IL1B IFNG
36 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 TNF IL1B IFNG
37 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.74 NOD2 IFNG CCL2
38 T cell chemotaxis GO:0010818 9.73 CXCR3 CCL3
39 chemokine-mediated signaling pathway GO:0070098 9.73 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
40 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL1B IL18
41 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL1B IL18
42 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 TNF IL1B IL18 CCL3 CCL2
43 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
44 T-helper 1 type immune response GO:0042088 9.71 IL18 HLA-DRB1
45 detection of bacterium GO:0016045 9.71 NOD2 HLA-DRB1
46 positive regulation of NMDA glutamate receptor activity GO:1904783 9.7 IFNG CCL2
47 positive regulation of chemokine biosynthetic process GO:0045080 9.7 TNF IL1B IFNG
48 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
49 interleukin-6 production GO:0032635 9.69 IL1B IL18
50 astrocyte cell migration GO:0043615 9.69 CCL3 CCL2

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.33 CCL3 CCL2 CCL18
2 chemokine activity GO:0008009 9.26 CXCL9 CCL3 CCL2 CCL18
3 cytokine activity GO:0005125 9.23 TNF IL1B IL18 IFNG CXCL9 CCL3
Sources

Sources for Sarcoidosis 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....